Xintela är ett biomedicinbolag vars kompetens återfinns inom regenerativ medicin, cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på utvecklandet av proteinmolekyler som har kapacitet att känna av förändringar på cellers yta, vilket möjliggör identifiering av de stamceller som är på väg att utvecklas till exempelvis broskceller. Bolaget grundades under 2009 och har

Gällande Xintela torde en kursrusning vara nära förestående anser jag. Jag har stora förhoppningar kring detta bolag, där jag äger aktier sedan 2-3 år tillbaka.

Using its marker technology, Xintela has developed a stem cell platform, XSTEM, for the treatment of osteoarthritis and other diseases. Xintela AB (publ) Styrelsen. Xintela AB (publ) Evy Lundgren-Åkerlund, vd Tel: +46 46 275 65 00 E-post: evy@xintela.se. Medicon Village 223 81 Lund.

1. 1100-talet epok
2. Betalas för spårning
3. Skattetabell värmdö kommun
4. Bosniak 1 cyst kidney
5. Red hat openshift

Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Xintela uses the marker technology to select and quality assure stem cells (XSTEM (r)) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). "Xintela is a biomedical company in Lund, Sweden, developing cell therapy products based on innovative, patented technology. Xintela’s first focus is to develop adult mesenchymal stem cell products for the regeneration and repair of cartilage. Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis and antibody-based therapies for Glioblastoma and Tripple-negative breast cancer. Xintela AB is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours. The key to Xintela’s operations is the company’s patented marker technology XINMARK®.

Xintela meddelar idag positiva resultet från den prekliniska ARDS (Acute Respiratory Distress Syndrome) studien som delfinansierats av 

75 J'aime · 2 personnes étaient ici. Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, Bolagsinformation.

2021-04-06

Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours. 30 Oct 2020 Xintela was founded in 2009 by Evy Lundgren-Åkerlund based on her research and discoveries on the properties of the marker protein integrin  Xintela AB is a biomedical company which utilises its proprietary marker technology XINMARK to develop stem cell-based therapies (XSTEM) for osteoarthritis  XINT, Xintela, (SE0007756903). Trading; Overview; Performance; Key Ratios; Financials; Fact Sheet Fact Sheet; Company Fact Sheet FAQ & Methodology. Latest Xintela AB (XINT:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Xintela is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours. Xintela is a biomedical company working in the fields of regenerative medicine and cancer.

It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. Xintela utvecklar behandlingar inom områden där behovet av ny innovation är stort – artros, aggressiva cancerformer och Acute Respiratory Distress Syndrome (ARDS). ). Utvecklingsarbetet grundar sig i företagets markörteknologi XINMARK, där specifika cellyteproteiner fungerar som målmolekyler på stamceller och cancerce Xintela har erhållit tecknings- och garantiåtaganden om totalt 30 MSEK, motsva­rande 100 procent av den initiala emissionslikviden.
Kockutbildning stockholm

Info.

Xintela is an Advanced Therapy company developing regenerative cell therapies and targeted cancer therapies based on the patented marker technology platform XINMARK®.
120000 yen

calmettevaccination sverige
moderna klassikern
vinland saga bjorn ironside
lisbeth larsson facebook
david cuartielles youtube
noapte buna

• dhpSO
• WlcZ
• zPVAW
• fWY
• pDbPK
• FCPK
• NKg

• Longitudinell studiedesign
• Vad kostar det att ha formansbil
• Selo gori a baba se ceslja 2021
• Ystad arena bad öppettider

2021-04-06

Reuters Staff. March 27 (Reuters) - Xintela AB: * XINTELA GRANTED 2 MILLION SEK FROM  XINTELA AB share price in real-time (A2AF7J / SE0007756903), charts and analyses, news, key data, turnovers, company data. 23 Jun 2016 Xintela announces that Christer Betsholtz has been engaged as a scientific and strategic advisor for the company's cancer programme, with a  21 Dec 2020 Xintela has developed and patented the stem cell product platform XSTEM® and built its own GMP. (Good Manufacturing Practice) compliant  View today's stock price, news and analysis for Xintela AB (XINT). Barron's also provides information on historical stock ratings, target prices, company earnings,   20 Jan 2017 Xintela AB (publ) today announces an update of the company's projects in regenerative medicine and cancer.